Additional Advances in Acute Leukemia Research and Clinical Trials With Amir Fathi, MD

In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School and Program Director of the Center for Leukemia at Massachusetts General Hospital, served as faculty for Therapy of B-Cell Acute Lymphoblastic Leukemia (ALL): an Evolving Landscape, a session presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans. In this interview, Dr. Fathi elaborates on these exciting developments in the ever-changing treatment landscape for acute leukemia.  

Continue reading

Therapy of B-Cell Acute Lymphoblastic Leukemia, An Evolving Landscape: Amir Fathi, MD

Oncology Data Advisor™ · Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Ranathunga et al, 2020). Although survival has improved in recent years due to considerable advances in treatment, the rate of relapse remains high (ASCO, 2021; Samra et al, 2020). One reason for this is that older patients are o...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.